Publications by authors named "Madhavi Rudraraju"
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
December 2024
Background: Denifanstat, an oral fatty acid synthase (FASN) inhibitor, blocks de-novo lipogenesis, a key pathway driving progressive lipotoxicity, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to examine the safety and efficacy of denifanstat for improving liver histology in individuals with MASH and moderate to advanced fibrosis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2b trial was conducted at 100 clinical sites in the USA, Canada, and Poland.
Article Synopsis
- * A phase 3 trial is underway, where adult participants with confirmed NASH are randomly assigned to receive either resmetirom (80 mg or 100 mg) or a placebo, with primary goals of NASH resolution and improvement in fibrosis after 52 weeks.
- * In the trial's results, a significantly higher percentage of patients taking resmetirom experienced NASH resolution and fibrosis improvement compared to those on placebo, along with notable reductions in cholesterol levels, although some participants did report diarrhea.
Scleritis associated with hepatitis C: a case report and review of literature.
Ann Ophthalmol (Skokie)
March 2009
There has been an increase in the complications associated with hepatitis C. Scleritis is one of the complications of the condition that is not routinely suspected, and thus underdiagnosed or missed, leading to delay in initiation of treatment. This case report will bring that to the attention of ophthalmologists so necessary systemic therapy can be instituted in a timely fashion.
View Article and Find Full Text PDF